#CLC WORKBENCH REGISTRATION#
#CLC WORKBENCH SOFTWARE#
#CLC WORKBENCH LICENSE#
#CLC WORKBENCH FREE#

Polymyxins (colistin and polymyxin B) have been used for the treatment of CRE in recent years, but increased rates of resistance to these antimicrobial agents have been documented. However, infections due to CRE demand the use of other antimicrobial classes, usually in combined therapy 10. Over the years, KPC-producing organisms have spread in Brazilian hospitals, and currently, KPC is as frequent as 96% among the carbapenemase-producing Enterobacterales (CRE) organisms identified in a multicenter study with ten Brazilian institutions 8.Ĭarbapenems are still used for treatment of Gram-negative infections in Brazil, mainly in intensive care units 9. The KPC enzyme was first described in the United States in 1996 and identified in Brazil 10 years later 7. Although resistance to carbapenems in Gram-negative bacteria may be the result of efflux systems, impermeability and altered transpeptidases, the main mechanism associated with this phenotype is the production of acquired β-lactamase enzymes 3.Ĭarbapenemases are widely spread worldwide, and Klebsiella pneumoniae carbapenemase (KPC) is the leading enzyme in terms of frequency, including in Brazil 4, a continental country with high rates of hospital-acquired infections and antimicrobial resistance 5, 6.

pneumoniae, underscoring the urgent need for stringent policies for antimicrobial stewardship to preserve the activity of such drugs.Ĭarbapenem-resistant Klebsiella pneumoniae ranks among the top priority pathogens according to the World Health Organization and the Centers for Disease Control and Prevention 1, 2. Our findings showed limited susceptibility to antimicrobial drugs employed for infection treatment of carbapenem-resistant K. Although high in vitro susceptibility rates were detected for meropenem-vaborbactam and cefiderocol, only ceftazidime-avibactam is currently available in Brazil. The 97 isolates were distributed into 17 different sequence types, with a predominance of ST11 (37.4%). Colistin and polymyxin B were active against 58.6% of the isolates. The most active antimicrobial agents were meropenem-vaborbactam, cefiderocol, and ceftazidime-avibactam, with sensitivities higher than 90% resistance to ceftazidime-avibactam was associated with KPC-33 or KPC-44 variants. The majority of the isolates (54.6%) were classified as extensively drug resistant or multidrug resistant (44.3%) one isolate showed a pandrug resistance phenotype. Clonality, resistance and virulence genes were detected by whole-genome sequencing. We evaluated the in vitro activity of novel antimicrobial drugs/combinations against 97 KPC-producing Klebsiella pneumoniae isolates recovered from different hospitals in Brazil during 2021–2022. Therefore, evaluation of novel antimicrobial drugs is needed to identify potential treatments with better outcomes.

First-time users of CLC Gx on our workstation computers must complete the Workstation Request Form.Carbapenem-resistant Klebsiella pneumoniae (CRKP) are highly disseminated worldwide, and isolates co-resistant to other antimicrobial agents pose a threat to effective antimicrobial therapy.

#CLC WORKBENCH SOFTWARE#

All USC users can freely access the software on our workstation computers.

Equipped with dual-CPU and 512GB RAM, one of our workstation computers is configured specifically to handle large data set and computationally intensive tasks such as de novo genome assembly and sequencing alignment.

Wilson Dental Library, the University Park Campus.Norris Medical Library (RM203A), the Health Sciences Campus.The software has been installed on multiple workstation computers:.On workstation computers in the libraries.

#CLC WORKBENCH REGISTRATION#

Mandatory registration is required for installing CLC Gx on your computer. Please submit the Local Installation Request Form.The computer must be connected to the USC network, either via Ethernet cable on campus or via USC VPN when using wireless (applies to both on- and off-campus wireless connections).

Minimum hardware requirement for de novo assembly, metagenomics, and raw reads alignment:: 32GB RAM and Intel i7-6700 or faster processor.

Minimum hardware requirement for general use: 16GB RAM and Intel i7-2600 or faster processor.

#CLC WORKBENCH LICENSE#

The license consists of TWO concurrent user seats.

#CLC WORKBENCH FREE#

USC has licensed CLC Gx for the free use of USC faculty, students and staff.

Clc workbench